ClinicalTrials.gg
RecruitingNCT06320067STAMPEDE2Updated Sep 26, 2025

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

A Phase 3 interventional study of Stereotactic Ablative Body Radiotherapy (SABR) and 177Lu-PSMA-617 in Prostate Cancer Metastatic, sponsored by University College, London. Recruiting at 18 sites in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,360
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Prostatic Neoplasms by University College, London — 9 open to participants now, 17 under way, 3 of them phase 3. Prostatic Neoplasms · University College, London.

Planned enrollment
3rd of 20
3,360 · median 454
Started
2024
with 2 others
Phase 3
6 of 32
2 open now
Primary completion
2031-04
later than 16 of 16 live
Registered
26th of 32
by date

Among the 32 studies in Prostatic Neoplasms by University College, London, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 16 of the 16 other live ones, and was the 26th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 32 studies in Prostatic Neoplasms by University College, London are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Prostatic Neoplasms by University College, London, or all of them as a file.
02

Study summary

STAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple hospitals across the UK are involved. University College London is running the trial.

Each comparison within the trial has its own control arm where people get the best standard of care (Arm A) versus a research arm where a new treatment is added to standard of care.

Participants are allocated to an arm by a computerised system with a 50% chance of getting the research treatment.

Comparison S: Arm A versus Arm S (Stereotactic Ablative Body Radiotherapy (SABR)) - Tests whether giving targeted doses of radiotherapy (SABR) to parts of the body where the cancer has spread slows the spread of the cancer and improves survival. 2476 people will be in this comparison.

Comparison P: Arm A versus Arm P (PSMA-Lutetium (177Lu-PSMA-617)) - Tests whether giving a radioactive material (177Lu-PSMA-617) that targets prostate cancer cells slows the spread of the cancer and improves survival. 1756 people will be in this comparison.

All participants will be followed up with scans and tests to monitor their cancer. Doctors will check for any side effects from the treatments. Treatments will be stopped if side effects are serious, or people no longer wish to take the treatments.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

Keywords

  • Hormone sensitive metastatic prostate cancer
  • Stereotactic ablative body radiotherapy (SABR)
  • PSMA-Lutetium
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Registration Inclusion Criteria:

  1. At least 18 years old.
  2. Histological confirmation of prostate adenocarcinoma or a strong clinical suspicion of prostate cancer with a plan to confirm the diagnosis formally before any future randomisation.
  3. Confirmation of site(s) on CT/MRI and either bone or PET scan. Patients with metastatic disease meeting any of the following criteria are eligible:

    • Metastatic disease to the bone (in any distribution).
    • Non-regional lymph node metastases of any size or distribution. Lymph nodes that are only visible on PET will not be eligible as sites of metastasis. Note: If lymph nodes are the only site of metastases, then at least one must be at least 1.5cm in short axis AND outside of the pelvis.
    • Visceral metastases of any size or distribution.
  4. Clinical presentation is:

    A. de novo. OR B. with; (1) continuing hormone sensitivity in the opinion of the investigator, and; (2) all hormone treatments (e.g., ADT and ARPI) will have been completed ≥2 years prior to any future randomisation into any of the comparisons, and; (3) will have received ≤3 years total of ADT at the point of randomisation into any comparison.

    Note: the dates will be checked again at randomisation. It is the responsibility of the investigator to account for the time between registration and randomisation into any comparison.

  5. Long-term androgen deprivation therapy (ADT) has started or there is an intention to start for a minimum of 2 years.
  6. 0-2 or, if WHO Performance Status 3, deemed to be due to metastatic burden and expected to improve with ADT. Note: Improvement to WHO status 0-2 will be checked again at randomisation into any subsequent comparison.

    Note: For WHO performance status definitions see Appendix 1.

  7. Willing and able to comply with trial treatments.
  8. Patient has signed form for registration into the STAMPEDE2 Trial platform.

Registration Exclusion Criteria:

  1. Clinically and pathologically overt small cell carcinoma.
  2. Metastatic brain disease or .
  3. Any active (i.e., progressing or requiring any treatment in the previous 36 months) other than prostate cancer (except non-muscle invasive bladder cancer; nonmelanomatous skin cancer or a malignancy that is considered cured with minimal risk of recurrence).
  4. Any other medical condition that in the investigator's opinion means the participant is unfit or unsuitable for long-term ADT or the trial treatments in the comparison for which they are being considered.

Eligibility Criteria For Comparison S Testing SABR:

Patients who meet the general eligibility criteria can be considered for the SABR comparison. Recruiting sites will assess metastatic disease burden using CT/MRI scans and baseline Tc-99m bone scan or PET scan to assess number of metastatic bone and non-regional lymph node foci, and presence of visceral metastases. Patients will be classified as either 'SABR-eligible' or 'SABR-ineligible' using the following definition.

Definition of SABR-eligible disease:

Patients will be classified as SABR-eligible if they meet all the following criteria:

  • 1-5 metastatic lesions (including either bone and/or non-regional lymph node sites).
  • Clinician determination that metastatic lesions are considered suitable for SABR on technical grounds (such as proximity of dose limiting normal tissue or tumour volume). Note: Clinical determination can consider next-generation imaging (e.g., PSMA PET-CT or WBMRI) where available. It is the investigator's responsibility to consider the impact of any findings on the suitability of SABR for the patient. Any next-generation imaging used prior to randomisation should be declared at randomisation so that it can be used as a stratification factor.
  • Absence of visceral metastases.

Otherwise, patients will be classified as SABR-ineligible.

In addition to the general registration eligibility criteria, they need to meet all the following criteria for entry into Comparison S:

  1. Patient still meets all eligibility criteria for registration in Section 4.4.
  2. Histological confirmation of prostate adenocarcinoma.
  3. Newly diagnosed (de novo) metastatic disease that is considered eligible for SABR according to the above definition.
  4. Patient has started ADT and randomisation is ≤12 weeks since the start of ADT.
  5. WHO performance status 0-2 (see Appendix 1).
  6. Patient has provided signed informed consent for participation in Comparison S.

Exclusion Criteria For Comparison S Testing SABR:

  1. Patient has relapsed prostate cancer.
  2. Prior radical treatment to the prostate (e.g., radical surgery and/or radiotherapy).
  3. Intracranial metastatic disease.
  4. Prior treatment to a metastatic site (e.g., radiotherapy, surgery or RFA).
  5. Significant or progressive neurological deficit such that emergency (within 24 hours) surgery or radiation required (e.g., metastatic spinal cord compression, or impingement of the cord or any other clinical scenario whereby urgent radiotherapy to the spine is required).
  6. Any condition or co-morbidities that, in the judgement of the clinician, preclude procedures required to facilitate radiotherapy delivery e.g.:

    1. Disease staging and follow-up.
    2. Radiotherapy planning procedures.
  7. Any condition or co-morbidities that, in the judgement of the clinician, preclude the safe delivery of radiotherapy to the prostate (± pelvic lymph nodes) and/or metastases e.g., inflammatory bowel disease, significant systemic connective tissue disorder, radiological evidence of idiopathic pulmonary fibrosis).
  8. Active malignancy other than prostate cancer within the last 36 months.

Eligibility Criteria For Comparison P Testing 177LU-PSMA-617:

In addition to the general eligibility criteria, patients need to meet the following criteria for entry into Comparison P:

  1. Patient still meets all eligibility criteria for registration.
  2. Histological confirmation of prostate adenocarcinoma.
  3. Patient meets the definition of SABR ineligible disease.
  4. Patients must have adequate organ function as indicated by blood tests within 4 weeks prior to randomisation:

    Bone marrow function

    1. ≥1.5 x 109/L
    2. ≥100 x 109/L
    3. ≥9g/dL, independent of transfusions for at least 28 days Hepatic function

    <!-- -->

    1. Total ≤2 x . For patients with Gilbert's Syndrome ≤3 x ULN is permitted.
    2. and/or ALT performed with all results ≤3 × ULN or ≤5 x ULN for patients with liver metastasis Renal Function

    <!-- -->

    1. EGFR ≥50 mL/min/1.73m2 calculated using the formula
    2. Albumin ≥25g/L
  5. Patient has started ADT and randomisation is ≤12 weeks since start of current ADT.
  6. If relapsed disease, prior LHRH agonist/antagonist with or without first generation antiandrogen use in the /neo-adjuvant setting, hormone treatment must have been discontinued ≥2 years prior to randomisation AND must not have exceeded a total of >3 years of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy.
  7. WHO performance status 0-2 (see Appendix 1).
  8. Patient has provided signed informed consent for participation in Comparison P.

Exclusion Criteria For Comparison P Testing 177Lu-PSMA-617:

  1. Prior treatment with any of the following:

    1. Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223
    2. PSMA-targeted radioligand therapy
  2. Symptomatic cord compression, or clinical/radiological findings indicative of impending cord compression.
  3. Any condition that precludes raised arms position.
  4. Unmanageable bladder outflow obstruction or urinary incontinence. Note: bladder outflow obstruction or urinary incontinence which is manageable and controlled with best available standard of care (incl. drainage, pads) is permitted.
  5. Imaging Sub-study only: to MRI (e.g., pacemakers, except MRI compatible pacemakers).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,360 participants (estimated)

Study arms

  • Active comparator
    Arm A of SABR Comparison

    SoC (ADT + ARPI ± docetaxel + local RT)

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Signalling Inhibitor (ARPI) · Radiation: Radiotherapy to Prostate ± Pelvic Nodes · Drug: Docetaxel

  • Experimental
    Arm S of SABR Comparison

    SoC (ADT + ARPI ± docetaxel + local RT) + SABR

    Radiation: Stereotactic Ablative Body Radiotherapy (SABR) · Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Signalling Inhibitor (ARPI) · Radiation: Radiotherapy to Prostate ± Pelvic Nodes · Drug: Docetaxel

  • Active comparator
    Arm A of 177Lu-PSMA-617 Comparison

    SoC (ADT + ARPI ± docetaxel ± local RT)

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Signalling Inhibitor (ARPI) · Radiation: Radiotherapy to Prostate ± Pelvic Nodes · Drug: Docetaxel

  • Experimental
    Arm P of 177Lu-PSMA-617 Comparison

    SoC (ADT + ARPI ± docetaxel ± local RT) + 177Lu-PSMA-617

    Other: 177Lu-PSMA-617 · Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Signalling Inhibitor (ARPI) · Radiation: Radiotherapy to Prostate ± Pelvic Nodes · Drug: Docetaxel

Interventions

  • RadiationStereotactic Ablative Body Radiotherapy (SABR)

    SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.

    Also known as: Stereotactic body radiotherapy (SBRT)

  • Other177Lu-PSMA-617

    177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).

    Also known as: Lutetium (177Lu) Vipivotide Tetraxetan, AAA617, Pluvicto

  • DrugAndrogen Deprivation Therapy (ADT)

    Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.

  • DrugAndrogen Receptor Signalling Inhibitor (ARPI)

    Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines. Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess. Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles. Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring. Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles.

  • RadiationRadiotherapy to Prostate ± Pelvic Nodes

    Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).

  • Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as time from randomisation to death from any cause. The final reporting times of OS for each comparison below will depend on the recruitment rates and the accuracy of assumed median survival times in the sample size calculations.

    Time frame: Final analysis for each comparison triggered when adequate number of death events have occurred in control arm of each comparison. Anticipate final reporting for OS in Comparison S: ~84 months (7 years) from FPFV, P: ~64 months (5.3 years) from FPFV.

Secondary outcomes

  1. Failure-Free Survival (FFS)

    Time from randomisation until the first of: * Biochemical progression * Clinical progression such as symptomatic local progression leading to intervention * Radiographic confirmed progression including local progression, pelvic lymph node progression, progression of an existing metastatic site or development of new metastatic site defined as lymph nodes outside the pelvis, bone or organ involvement * Symptomatic skeletal-related events secondary to cancer progression * Death from any cause

    Time frame: Up to 10 years from randomisation. FFS is declared as a secondary outcome and is not part of sample size calculations, nor timelines for the study.

  2. Radiographic Progression-Free-Survival (rPFS)

    Time from randomisation until the first of: * Radiographic confirmed progression of an existing metastatic site or development of a new metastatic site defined as lymph nodes outside the pelvis, bone or organ involvement * Symptomatic skeletal-related events secondary to cancer progression * Death from any cause

    Time frame: Up to 10 years from randomisation. rPFS is declared as a secondary outcome and is not part of sample size calculations, nor timelines for the study.

  3. Prostate cancer specific survival (PCSS)

    Time from randomisation to death from prostate cancer.

    Time frame: Up to 10 years from randomisation. PCSS is declared as a secondary outcome and is not part of the sample size calculations, nor timelines for the study.

  4. Safety through reporting of SAEs

    Time frame: S: until 6 months after randomisation; P: until 6 months after randomisation or 40 days after completion or permanent discontinuation of an IMP 177Lu-PSMA-617 (whichever is furthest); N: until 30 days after permanent discontinuation of an IMP

  5. Toxicity using CTCAE classification and reporting of all Adverse Events that are ≥ grade 3 or grade 1 and 2 leading to a change in trial treatment

    Time frame: All safety and toxicity data will be presented by randomised group. The exact nature of this will be pre-specified in the statistical analysis plan that is still in development.

  6. Compliance with randomised allocation. Formal definitions for compliance with treatment will be pre-specified in the statistical analysis plan. This is still in development.

    Time frame: Randomisation until death or end of trial treatment (up to 10 years from randomisation).

  7. Resource use for cost-effectiveness assessment

    Time frame: Randomisation until death or end of trial treatment (up to 10 years from randomisation).

  8. EQ-5D-5L questionnaire for QoL and cost effectiveness assessment

    Time frame: From date of randomisation until death or end of trial, whichever came first (up to 10 years from randomisation). The end of the trial will be determined by the timelines described in the primary outcomes section.

07

Study locations

18 of 18 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Data will be shared according to the CTU's controlled access approach based on principles outlined in the trial protocol. Requests for sharing data will need to provide detail on the specific requirements, proposed research, qualifications of researchers and publication plan. All non-identifiable data will be available for sharing if approved following the CTU review process. Access to the digital image repository and the stored pathological tissue from researchers outside of the MRC CTU will be obtained through a formal data sharing application detailing the specific requirements, proposed research, investigator qualifications and publication plan. Applications for access to tissue are required separately from access to the shared clinical data.

Supporting information: Study protocol

Time frame: It will become available for data sharing requests through the MRC CTU process following the primary analysis publication. Research data will be stored a minimum of 25 years.

Access criteria: Data will be available for sharing and researchers wishing to access STAMPEDE2 data should contact the Trial Management Group via the CTU Trial team using the study mailbox in the first instance. A formal data sharing process has been developed at the MRC CTU. Requests for sharing data will need to provide detail on the specific requirements, proposed research, qualifications of researchers and publication plan. The requests will be reviewed by the appropriate STAMPEDE2 committees. A data transfer agreement will be signed prior to the transfer of any information. All patients will be consented for future data sharing and if data requests are approved, only anonymised data will be sent using appropriately encrypted methods for data transfer.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Apr 2031, 82 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 82 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Mar 20, 2024
StartActual
Jun 11, 2024
Primary completionEst.
Apr 2031
CompletionEst.
Mar 2032
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06320067
Collaborators
Cancer Research UK, Novartis
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Jun 11, 2024
Primary completion
Apr 2031 (estimated)
Completion
Mar 2032 (estimated)
Last update
Sep 26, 2025

Study contacts

Pamela Niem
Contact
mrcctu.stampede2@ucl.ac.uk
+442076704921
Aaron Horsey
Contact
mrcctu.stampede2@ucl.ac.uk
+442076704921
Louise Brown
study director · MRC CTU at UCL
Nick James
principal investigator · Institute of Cancer Research, United Kingdom

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion